White Papers

BioPharm Suite

Save Time and Cost By Using BioPharm Clinical to In-Source Early Study Feasibility

Industry estimates suggest the cost of performing study feasibility can range from USD 50,000 to hundreds of thousands of dollars. Because it is largely a manual and inefficient process, it is also a time-consuming effort that not only increases your CRO budget but also burdens your clinical operations team with weeks or months of work time that could better spent elsewhere.

Small pharmaceutical and biotechnology companies are turning this trend around by utilizing tools such as BioPharm ClinicalTM to retain control over their time and budget and performing early study feasibility in-house rather than paying and waiting for a CRO to do it.

Read this white paper to learn how BioPharm Clinical helps companies achieve these goals with a simple three-step process that provides everything you need to determine early study feasibility.

8 Ways to Improve Your CRO and Services Sales to Pharma

The global biopharmaceutical industry is in a state of flux. As the costs of drug development and the risks of failure continue to escalate, companies are facing a fundamental imperative: the current model of bringing new drugs to market must change. This shift in philosophy represents a tremendous opportunity for CROs and service providers of all sizes and specialties to increase the value they provide to the global pharma community. Industry is relying more on strategic outsourcing and business development professionals can become trusted partners if they know how to find and capitalize on ideal opportunities before their peers. 

Read this white paper to learn eight strategies used by successful business development professionals to sell their services to pharma, from tracking drugs changing phase and monitoring new financing to identifying decision-making contacts.

Seven Proven Strategies to Choose Better Investigators
The primary factor in escalating drug development costs is the clinical trial process, with study delays costing sponsors millions of dollars every day the drug is not on the market. Once the protocol is designed, sponsors and CROs will transfer daily control to the sites and investigators who will implement the trial, often in numerous centers around the world. Choosing the right partners saves unnecessary cost and is a critical success factor for entire clinical programs.

Based on our experience working with clients, including leading global pharmaceutical companies and CROs, we have compiled the following best practices to help you improve your investigator selection process.

The Emergence of Real-Time Intelligence to Overcome Limits of Traditional Biopharma Market Research
With heightened competition throughout the global biopharma landscape, the demand for business intelligence (BI) has intensified – as has the need for new tools and information to provide BI departments with an actionable edge.

This white paper outlines innovative new methods being used by BI thought leaders to achieve that elusive edge.

Wealth Prospecting

Prospecting Best Practices for High Net Worth Individuals
The most successful private wealth advisors are able to identify opportunities in their territory with a high likelihood to close, and have the insight to react quickly (e.g. first) to win the client. This white paper highlights several of the innovative prospecting methods being used by elite private wealth advisors to find and attract new clients even in this uncertain global economy.

Custom Data Services

7 Proven Ways Data Can Improve Your FA Business Development
The most successful asset managers are able to target and close deals with Financial Advisors in all ecomonic climates by gaining an information edge over the competition. The key is hidden inside your internal and third-party data. The following seven proven strategies will enable your sales and marketing team to take more value from your data in order to find targeted FA opportunities at precise times to improve your win ratio and ROI.